CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 25 enrolled
Drug / intervention
Tolipalimab +1 moredrug
Likely dose
Tolipalimab 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03854838
NCT03854838Phase 2Unknown
CompareCT.gov

A Single Center 、Single Arm Phase I/II Clinical Trial of Intensity-modulated Radiotherapy Combined With Toripalimab in the Treating of Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Sun Yat-sen University·interventional·Posted Feb 26, 2019·Updated Apr 29, 2022

In Brief

A Phase 2 clinical trial evaluating Tolipalimab and Reirradiation for Nasopharyngeal Carcinoma and 3 related conditions. Targeting 25 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of intensity-modulated radiation therapy combined with toripalimab in patients with the unresectable locally recurrent nasopharyngeal carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20192020202120222023202420252026
First PostedFeb 26, 2019
Enrollment StartMay 1, 2019
Primary CompletionFeb 1, 2021
Study CompletionFeb 1, 2023
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 7.3 years ago

Interventions

Tolipalimabdrug

Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.

Reirradiationradiation

intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks